Shattuck Labs (STTK) Expected to Announce Quarterly Earnings on Wednesday

Shattuck Labs (NASDAQ:STTK) is expected to issue its quarterly earnings data on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Trading Down 5.3 %

STTK opened at $1.26 on Wednesday. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76. The firm has a market cap of $60.15 million, a price-to-earnings ratio of -0.82 and a beta of 1.70. The company has a fifty day simple moving average of $1.19 and a 200 day simple moving average of $1.88.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on STTK. HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Shattuck Labs presently has an average rating of “Hold” and a consensus price target of $8.67.

Insider Activity

In other Shattuck Labs news, Director Redmile Group, Llc acquired 133,371 shares of the stock in a transaction dated Wednesday, December 4th. The shares were bought at an average price of $1.25 per share, with a total value of $166,713.75. Following the purchase, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This trade represents a 2.47 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is owned by insiders.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.